Drug General Information (ID: DDIZ6PFKNI)
Drug Name			Triethylenetetramine		Drug Info		Ferrous sulfate anhydrous		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Chelating Agents				Iron Supplement
Structure

Mechanism of Triethylenetetramine-Ferrous sulfate anhydrous Interaction (Severity Level: Moderate)
Complex formation Click to Show/Hide Mechanism Graph
Drug Name		Triethylenetetramine				Ferrous sulfate anhydrous
Mechanism		Binds to polyvalent cations				Polyvalent cations
Key Mechanism Factor 1
		Factor Name		Chelation
		Factor Description		Chelation is a direct drug interaction that usually involves the formation of dimers or trimers, resulting in larger complexes and poorer absorption.
Mechanism Description		Decreased absorption of Ferrous sulfate anhydrous due to formation of complexes caused by Triethylenetetramine

Recommended Action
Management		In general, mineral supplements and other products containing minerals should not be used in patients treated with trientine. However, iron deficiency may develop, particularly in children and menstruating or pregnant women. If necessary, iron may be given in short courses, provided that administration times are separated by at least two hours.

References
1	Product Information. Syprine (trientine). Aton Pharma, Lawrenceville, NJ.